Cargando…
Quality of outcome reporting in phase II studies in pulmonary tuberculosis
Tuberculosis (TB) remains a major killer amongst the infectious diseases. Current treatment involves a four-drug regimen for at least 6 months. New drugs and regimens are required to shorten treatment duration, reduce toxicity and combat drug resistance, but the optimal methodology to define the cri...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644328/ https://www.ncbi.nlm.nih.gov/pubmed/26566930 http://dx.doi.org/10.1186/s13063-015-1050-1 |